# Commission Regulation (EC) No 1837/97 of 24 September 1997 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance), Annex Extent: E+W+S+N.I. The Annexes to Regulation (EEC) No 2377/90 are hereby amended as follows: A.. Annex I is amended as follows: 2.. Antiparasitic agents 2.1. Agents acting against endoparasites 2.1.3. Benzimidazoles and pro-benzoimidazoles Pharmacologically active substance Marker residue Animal species MRLs Target tissues Other provisions ‘2.1.3.1. Febantel Sum of extractable residues which may be oxidized to oxfendazole sulphone Bovine, ovine, porcine, equidae 50 μg/kg Muscle 50 μg/kg Fat 500 μg/kg Liver 50 μg/kg Kidney Bovine, ovine 10 μg/kg Milk 2.1.3.2. Fenbendazole Sum of extractable residues which may be oxidized to oxfendazole sulphone Bovine, ovine, porcine, equidae 50 μg/kg Muscle 50 μg/kg Fat 500 μg/kg Liver 50 μg/kg Kidney Bovine, ovine 10 μg/kg Milk 2.1.3.3. Oxfendazole Sum of extractable residues which may be oxidized to oxfendazole sulphone Bovine, ovine, porcine, equidae 50 μg/kg Muscle 50 μg/kg Fat 500 μg/kg Liver 50 μg/kg Kidney Bovine, ovine 10 μg/kg Milk’ 5.. Corticoids 5.1. Glucocorticoids Pharmacologically active substance Marker residue Animal species MRLs Target tissues Other provisions ‘5.1.1. Dexamethasone Dexamethasone Bovine, porcine, equidae 0,75 μg/kg Muscle 2,0 μg/kg Liver 0,75 μg/kg Kidney Bovine 0,3 μg/kg Milk’ B.. Annex II is amended as follows: 1.. Inorganic compounds Pharmacologically active substance(s) Animal species Other provisions ‘1.29. Bromide, sodium salt All food producing mammals For topical use only’ C.. Annex III is amended as follows: 1.. Anti-infectious agents 1.2. Antibiotics 1.2.4. Cephalosporins Pharmacologically active substance Marker residue Animal species MRLs Target tissues Other provisions ‘1.2.4.1. Ceftiofur Sum of all residues retaining the betalactam structure expressed as desfuroylceftiofur Bovine 2 000 μg/kg Liver, kidney 200 μg/kg Muscle 600 μg/kg Fat 100 μg/kg Milk Provisional MRLs expire on 1. 1. 1999’ Porcine 4 000 μg/kg Kidney 3 000 μg/kg Liver 500 μg/kg Muscle 600 μg/kg Fat 1.2.6. Quinolones Pharmacologically active substance Marker residue Animal species MRLs Target tissues Other provisions ‘1.2.6.1. Danofloxacin Danofloxacin Bovine 900 μg/kg Liver 500 μg/kg Kidney 300 μg/kg Muscle 200 μg/kg Fat Provisional MRLs expire on 1. 1. 1999’ Chicken 1 200 μg/kg Liver, kidney 600 μg/kg Skin + fat 300 μg/kg Muscle 2.. Antiparasitic agents 2.1. Agents acting against endo-parasites 2.1.1. Benzimidazoles and pro-benzoimidazoles Pharmacologically active substance Marker residue Animal species MRLs Target tissues Other provisions ‘2.1.1.9. Netobimin Sum of netobimin and albendazole and metabolites of albendazole measured as 2-amino-benzimidazole sulphone Bovine, ovine, caprine 100 μg/kg Muscle, fat Provisional MRLs expire on 31. 7. 1999’ 1 000 μg/kg Liver 500 μg/kg Kidney 100 μg/kg Milk --- Source: https://www.legislation.gov.uk/eur/1997/1837/annex (the official version) Page: https://openlegislation.uk/eu-regulation-1997-1837/annex Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.